Oct 2 (Reuters) – Pfizer Inc.: * PFIZER’S LITFULO SIGNIFICANTLY IMPROVED FACIAL AND TOTAL BODY REPIGMENTATION IN PATIENTS WITH NONSEGMENTAL VITILIGO~ * PFIZER – TO SUBMIT LITFULO PHASE 3 DATA TO FDA
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)